Bélichard P, Pruneau D, Zhiri A
Centre de recherches des laboratoires Fournier, Daix, France.
Biochim Biophys Acta. 1993 Jul 21;1169(1):98-102. doi: 10.1016/0005-2760(93)90087-p.
This study was undertaken to determine if long-term oral administration of lovastatin (50 mg/kg per day) or fenofibrate (200 mg/kg per day) was affecting ubiquinone levels in the heart and the liver of cardiomyopathic hamsters. After 23 weeks of treatment, ubiquinone concentrations (CoQ9 + CoQ10) and ubiquinone ratio (CoQ10/CoQ9) were determined in the heart and in the liver. Our results indicate that lovastatin significantly decreased ubiquinone concentrations in the heart (-33%, P < 0.01) but not in the liver (-23%, NS) when compared to controls, whereas fenofibrate did not alter these parameters. Ubiquinone homologues were not equally decreased during lovastatin treatment: the ratio between CoQ10 and CoQ9 was significantly lowered in the heart (-33%, P < 0.001) and in the liver (-75%, P < 0.001) of lovastatin-treated animals. These results suggest that 3-hydroxymethylglutaryl-coenzyme A reductase inhibition (HMG-CoARI) associated with lovastatin treatment in cardiomyopathic hamsters is more marked in the liver than in the heart, while ubiquinone concentrations are more decreased in cardiac than in hepatic tissues. Our data also showed that fenofibrate had no effect on ubiquinone levels.
本研究旨在确定长期口服洛伐他汀（每天50毫克/千克）或非诺贝特（每天200毫克/千克）是否会影响心肌病仓鼠心脏和肝脏中的泛醌水平。治疗23周后，测定心脏和肝脏中的泛醌浓度（辅酶Q9 + 辅酶Q10）和泛醌比率（辅酶Q10/辅酶Q9）。我们的结果表明，与对照组相比，洛伐他汀显著降低了心脏中的泛醌浓度（-33%，P < 0.01），但未降低肝脏中的泛醌浓度（-23%，无统计学意义），而非诺贝特未改变这些参数。在洛伐他汀治疗期间，泛醌同系物的降低程度并不相同：在接受洛伐他汀治疗的动物的心脏（-33%，P < 0.001）和肝脏（-75%，P < 0.001）中，辅酶Q10与辅酶Q9的比率显著降低。这些结果表明，在心肌病仓鼠中，与洛伐他汀治疗相关的3-羟基-3-甲基戊二酰辅酶A还原酶抑制（HMG-CoARI）在肝脏中比在心脏中更明显，而泛醌浓度在心脏组织中的降低比在肝脏组织中更显著。我们的数据还表明，非诺贝特对泛醌水平没有影响。
